Acacia Pharma stock market launch to support nausea products
Acacia Pharma is to raise new funds through an initial global offering and launch on to the Euronext Brussels stock exchange
Acacia Pharma is to raise new funds through an initial global offering and launch on to the Euronext Brussels stock exchange
Decision follows EU regulators’ decision to back Crohn’s stem cell therapy
Deal could be worth 627.5 million euros
New trial data will be included in US and EU filings
The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.